The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Virtual Screening for Potential Inhibitors of Human Hexokinase II for the Development of Anti-Dengue Therapeutics
Open accessAbstract
Dengue fever, which is a disease caused by the dengue virus (DENV), is a major unsolved issue in many tropical and sub-tropical regions of the world. The absence of treatment that effectively prevent further viral propagation inside the human’s body resulted in a high number of deaths globally each year. Thus, novel anti-dengue therapies are required for effective treatment. Human hexokinase II (HKII), which is the first enzyme in the glycolytic pathway, is an important drug target due to its significant impact on viral replication and survival in host cells. In this study, 23.1 million compounds were computationally-screened against HKII using the Ultrafast Shape Recognition with a CREDO Atom Types (USRCAT) algorithm. In total, 300 compounds with the highest similarity scores relative to three reference molecules, known as Alpha-D-glucose (GLC), Beta-D-glucose-6-phosphate (BG6), and 2-deoxyglucose (2DG), were aligned. Of these 300 compounds, 165 were chosen for further structure-based screening, based on their similarity scores, ADME analysis, the Lipinski’s Rule of Five, and virtual toxicity test results. The selected analogues were subsequently docked against each domain of the HKII structure (PDB ID: 2NZT) using AutoDock Vina programme. The three top-ranked compounds for each query were then selected from the docking results based on their binding energy, the number of hydrogen bonds formed, and the specific catalytic residues. The best docking results for each analogue were observed for the C-terminus of Chain B. The top-ranked analogues of GLC, compound 10, compound 26, and compound 58, showed predicted binding energies of −7.2, −7.0, and −6.10 kcal/mol and 7, 5, and 2 hydrogen bonds, respectively. The analogues of BG6, compound 30, compound 36, and compound 38, showed predicted binding energies of −7.8, −7.4, and −7.0 kcal/mol and 11, 9, and 5 hydrogen bonds, while the top three analogues of 2DG, known as compound 1, compound 4, and compound 31, showed predicted binding energies of −6.8, −6.3, and −6.3 kcal/mol and 4, 3, and 1 hydrogen bonds, sequentially. The highest-ranked compounds in the docking analysis were then selected for molecular dynamics simulation, where compound 10, compound 30, and compound 1, which are the analogues of GLC, BG6, and 2DG, have shown strong protein-ligand stability with an RMSD value of ±5.0 A° with a 5 H bond, ±4.0 A° with an 8 H bond, and ±0.5 A° with a 2 H bond, respectively, compared to the reference molecules throughout the 20 ns simulation time. Therefore, by using the computational studies, we proposed novel compounds, which may act as potential drugs against DENV by inhibiting HKII’s activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00104 · Cited by 5,716
Dengue and Dengue Hemorrhagic Fever
Gubler, D. J. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.3.480 · Cited by 4,310
ProTox-II: a webserver for the prediction of toxicity of chemicals
Banerjee, P., Eckert, A. O., Schrey, A. K., & Preissner, R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky318 · Cited by 3,195
Tumor glycolysis as a target for cancer therapy: progress and prospects
Ganapathy-Kanniappan, S., & Geschwind, J.-F. H. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-152 · Cited by 1,395
Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances
Lionta, E., Spyrou, G., Vassilatis, D., & Cournia, Z. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666140929124445 · Cited by 1,165
Localization of the primary metabolic block produced by 2-deoxyglucose
Wick, A. N., Drury, D. R., Nakada, H. I., Wolfe, J. B., Britton, B., & Grabowski, R. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64988-9 · Cited by 780 · cited 1×
“This inhibits the production of glucose-6phosphate, ultimately inhibiting the glycolytic pathway [25].”
BackgroundVirtual screening with AutoDock: theory and practice
Cosconati, S., Forli, S., Perryman, A. L., Harris, R., Goodsell, D. S., & Olson, A. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2010.484460 · Cited by 695
Virtual Screening Strategies in Drug Discovery: A Critical Review
Lavecchia, A., & Giovanni, C. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990001 · Cited by 686
Cited by
Jeevanandam, J., Kiew, S. F., Boakye-Ansah, S., Lau, S. Y., Barhoum, A., Danquah, M. K., & Rodrigues, J. (2022) · Nanoscale · doi:10.1039/d1nr08144f · Cited by 483
Soni, V., Raizada, P., Singh, P., Cuong, H. N., S, R., Saini, A., Saini, R. V., Le, Q. V., Nadda, A. K., Le, T.-T., et al. (2021) · Environmental Research · doi:10.1016/j.envres.2021.111622 · Cited by 311
Elhaissoufi, W., Ghoulam, C., Barakat, A., Zeroual, Y., & Bargaz, A. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2021.08.014 · Cited by 298
Wang, G., Yu, H., Feng, X., Tang, H., Xiong, Z., Xia, Y., Ai, L., & Song, X. (2021) · LWT · doi:10.1016/j.lwt.2021.111208 · Cited by 60
Zidan, G., Greene, C. A., Etxabide, A., Rupenthal, I. D., & Seyfoddin, A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120452 · Cited by 39
Metadata
- Authors
- Tanbin, S., Ahmad Fuad, F. A., & Abdul Hamid, A. A.
- Venue
- BioTech
- Publisher
- MDPI AG
- Published
- 2020-12-28
- Volume
- 10
- Issue
- 1
- Pages
- 1
- ISSN
- 2673-6284 (ISSN-L)
- OpenAlex
- W3117841035
- Cited by
- 413
- References
- 54
- FWCI
- 41.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Virtual Screening for Potential Inhibitors of Human Hexokinase II for the Development of Anti-Dengue Therapeutics. https://app.cochat.ai/papers/10.3390/biotech10010001
- The paper
- Tanbin, S., Ahmad Fuad, F. A., & Abdul Hamid, A. A. (2020). Virtual Screening for Potential Inhibitors of Human Hexokinase II for the Development of Anti-Dengue Therapeutics. BioTech. https://doi.org/10.3390/biotech10010001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.